Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review
- PMID: 35210038
- DOI: 10.1016/j.jacc.2021.12.016
Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review
Abstract
There is a need to identify high-risk features that predict early-onset atherosclerotic cardiovascular disease (ASCVD). The authors provide insights to help clinicians identify and address high-risk conditions in the 20- to 39-year age range (young adults). These include tobacco use, elevated blood pressure/hypertension, family history of premature ASCVD, primary severe hypercholesterolemia such as familial hypercholesterolemia, diabetes with diabetes-specific risk-enhancing factors, or the presence of multiple other risk-enhancing factors, including in females, a history of pre-eclampsia or menopause under age 40. The authors update current thinking on lipid risk factors such as triglycerides, non-high-density lipoprotein cholesterol, apolipoprotein B, or lipoprotein (a) that are useful in understanding an individual's long-term ASCVD risk. The authors review emerging strategies, such as coronary artery calcium and polygenic risk scores in this age group, that have potential clinical utility, but whose best use remains uncertain. Finally, the authors discuss both the obstacles and opportunities for addressing prevention in early adulthood.
Keywords: atherosclerotic cardiovascular disease; enhancing factors; family history of premature ASCVD; risk factor; young adults.
Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosures Dr Rigotti received support from National Institutes of Health (NIH) grant # R01HL111821; has received grants from NCI, NIDA, and Achieve Life Sciences; has been a consultant for Achieve Life Sciences; and has received royalties from UpToDate. Dr Mora received support from NIH grant # K24HL136852; has received grants from the NIH, outside this work; and has been a consultant for Pfizer and Quest Diagnostics. Dr Khan has received support from American Heart Association grant #19TPA34890060 and the NIH grants P30AG059988 and P30DK092939, outside this work. Dr Navar has received funding for research to her institution from Bristol Myers Squibb, Esperion, Amgen, and Janssen; and has received honoraria and consulting fees from Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Esperion, Janssen, Lilly, Sanofi, Regeneron, NovoNordisk, Novartis, The Medicines Company, New Amsterdam, Cerner, 89Bio, and Pfizer. Dr Blaha has received grants from the NIH, the Food and Drug Administration, American Heart Association, Amgen Foundation, Bayer, and Novo Nordisk; and has served on advisory boards for Amgen, Sanofi, Regeneron, Novartis, Novo Nordisk, Bayer, Akcea, Kowa, 89Bio, Kaleido, Inozyme, and Roche. Dr Pencina has received funding outside the work from the nonprofit Doggone Foundation/McGill University Health Centre; has received grants from Regeneron/Sanofi and Amgen to his institution; and has served on an advisory board for Boehringer Ingelheim. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical